These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36017827)

  • 21. Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.
    Greenspoon J; Herrmann N; Adam DN
    CNS Drugs; 2011 Jul; 25(7):575-83. PubMed ID: 21623641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.
    Kurz A; Farlow M; Lefèvre G
    Int J Clin Pract; 2009 May; 63(5):799-805. PubMed ID: 19392927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease.
    Winblad B; Machado JC
    Expert Opin Drug Deliv; 2008 Dec; 5(12):1377-86. PubMed ID: 19040398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
    Farlow MR; Alva G; Meng X; Olin JT
    Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study.
    Gauthier S; Robillard A; Cohen S; Black S; Sampalis J; Colizza D; de Takacsy F; Schecter R;
    Curr Med Res Opin; 2013 Aug; 29(8):989-1000. PubMed ID: 23647369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transdermal rivastigmine in the treatment of Alzheimer's disease: current and future directions.
    Amanatkar HR; Grossberg GT
    Expert Rev Neurother; 2014 Oct; 14(10):1119-25. PubMed ID: 25201245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.
    Grossberg GT; Olin JT; Somogyi M; Meng X
    Int J Clin Pract; 2011 Apr; 65(4):465-71. PubMed ID: 21309961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
    Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
    Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.
    Lefèvre G; Sedek G; Jhee SS; Leibowitz MT; Huang HL; Enz A; Maton S; Ereshefsky L; Pommier F; Schmidli H; Appel-Dingemanse S
    Clin Pharmacol Ther; 2008 Jan; 83(1):106-14. PubMed ID: 17522596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease.
    Nieto RA; Deardorff WJ; Grossberg GT
    Expert Opin Pharmacother; 2016; 17(6):861-70. PubMed ID: 26918774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily).
    Zhang ZX; Hong Z; Wang YP; He L; Wang N; Zhao ZX; Zhao G; Shang L; Weisskopf M; Callegari F; Strohmaier C
    CNS Neurosci Ther; 2016 Jun; 22(6):488-96. PubMed ID: 27012596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon).
    Forette F; Anand R; Gharabawi G
    Eur J Neurol; 1999 Jul; 6(4):423-9. PubMed ID: 10362894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety/Tolerability and efficacy of rivastigmine in taiwanese patients with Alzheimer's disease: a prospective post-marketing surveillance study.
    Chiu PY; Dai DE; Hsu HP; Lee C; Lin JJ; Kuo HC; Huang YC; Liu YC; Tsai CP
    Clin Drug Investig; 2009; 29(11):729-38. PubMed ID: 19813776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions.
    Adler G; Mueller B; Articus K
    Int J Clin Pract; 2014 Apr; 68(4):465-70. PubMed ID: 24588972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.
    Cagnin A; Cester A; Costa B; Ermani M; Gabelli C; Gambina G;
    Neurol Sci; 2015 Mar; 36(3):457-63. PubMed ID: 25394739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors Associated with Greater Adherence to and Satisfaction with Transdermal Rivastigmine in Patients with Alzheimer's Disease and Their Caregivers.
    Riepe M; Weinman J; Osae-Larbi J; Mulick Cassidy A; Knox S; Chaves R; Müller B
    Dement Geriatr Cogn Disord; 2015; 40(1-2):107-19. PubMed ID: 26066776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease.
    Farlow MR; Grossberg GT; Sadowsky CH; Meng X; Velting DM
    Alzheimer Dis Assoc Disord; 2015; 29(2):110-6. PubMed ID: 25437301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.
    Han HJ; Kim BC; Lee JY; Ryu SH; Na HR; Yoon SJ; Park HY; Shin JH; Cho SJ; Yi HA; Choi MS; Heo JH; Park KW; Kim KK; Choi SH
    Dement Geriatr Cogn Disord; 2012; 34(3-4):167-73. PubMed ID: 23051684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease.
    Blesa R; Ballard C; Orgogozo JM; Lane R; Thomas SK
    Neurology; 2007 Jul; 69(4 Suppl 1):S23-8. PubMed ID: 17646620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.